About
Antibody drug conjugates (ADCs) are powerful therapeutics that combine targeted monoclonal antibodies with cytotoxic drugs. To minimize toxicity, it is crucial to remove unconjugated drug molecules from the reaction mixture during ADC synthesis. Traditional purification methods involve size-exclusion chromatography and ultrafiltration, which can be time-consuming and costly.
In this webinar, we demonstrate how the µPULSE-TFF system offers a single-step scalable purification method for ADCs and other macromolecules modified with small molecules.
1. Efficient purification: The system automates antibody-drug conjugate purification, resulting in high purity.
2. Cost-effectiveness: The instrument offers a cost-effective alternative to traditional purification methods by reducing process time and the number of steps.
3. Scalability: The µPULSE is designed for scalability, allowing for easy handling of larger volumes of ADCs or other macromolecules.
4. High yield: It effectively removes unconjugated drug molecules from ADCs with up to 100% hold-up recovery, resulting in a high yield.
About the Speaker:
Muhammad Sajed is currently working at FORMULATRIX as an application scientist for the µPulse-TFF system and its applications in biological research. His areas of expertise include the production and purification of therapeutic enzymes, cell culturing, and industrial biotechnology. Before joining FORMULATRIX, he held positions as a research officer at the University of Punjab and as a lecturer at Lahore Garrison University.